Skip Navigation


Carcinogenesis Advance Access originally published online on August 12, 2004
Carcinogenesis 2004 25(12):2473-2478; doi:10.1093/carcin/bgh263
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
25/12/2473    most recent
bgh263v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Wagner, K.
Right arrow Articles by Försti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wagner, K.
Right arrow Articles by Försti, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis vol.25 no.12 © Oxford University Press 2004; all rights reserved.

ARTICLE

The insulin-like growth factor-1 pathway mediator genes: SHC1 Met300Val shows a protective effect in breast cancer

Kerstin Wagner1,6, Kari Hemminki1,2, Ewa Grzybowska3, Rüdiger Klaes4, Dorota Butkiewicz3, Jolanta Pamula3, Wioletta Pekala3, Helena Zientek3, Danuta Mielzynska5, Ewa Siwinska5 and Asta Försti1,2

1 Division of Molecular Genetic Epidemiology C050, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany, 2 Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden, 3 Department of Tumor Biology, Centre of Oncology, Maria Sklodowska-Curie Institue, Gliwice, Poland, 4 Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany and 5 Department of Genetic Toxicology, Institute of Occupational Medicine and Environmental Health, Sosnowiec, Poland

6 To whom correspondence should be addressed. Tel: +49 6221 421811; Fax: +49 6221 421810; Email: k.wagner{at}dkfz.de

The insulin-like growth factor 1 (IGF-1) pathway plays an important role in regulating cell proliferation, differentiation and apoptosis. IRS1, IRS2 and SHC1 are the key mediators for the downstream pathway processes. Genetic variation within these genes may lead to altered signalling. We screened IRS1, IRS2 and SHC1 for published coding region polymorphisms and choose five of them, IRS1 Ala804Ala and Gly972Arg, IRS2 Cys816Cys and Gly1057Asp and SHC1 Met300Val, for further analysis. We studied the association of the polymorphisms with breast cancer risk using a case–control design with Polish familial breast cancer cases and respective controls. For the polymorphisms in IRS1 and IRS2 no differences in the allele, genotype or haplotype distributions could be detected between the case and control subjects. Carriers of the variant allele of the SHC1 polymorphism were at decreased risk of breast cancer (OR 0.54, 95% CI 0.32–0.90, P = 0.016). A non-significant trend for a protective effect of the SHC1 Val300 allele was also seen in an independent population consisting of German familial breast cancer cases and matched controls. The joint analysis after Mantel–Haenzsel adjustment of the two populations gave an OR of 0.62 (95% CI 0.41–0.93, P = 0.02) for the SHC1 Val300 carriers. A stronger effect was detected in women diagnosed below the age of 50 (OR 0.54, 95% CI 0.32–0.89, P = 0.01). A genotype combination analysis of the non-synonymous polymorphisms in the IRS1, IRS2 and SHC1 genes did not show any effect on breast cancer risk.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. Diorio, J. Brisson, S. Berube, and M. Pollak
Genetic Polymorphisms Involved in Insulin-like Growth Factor (IGF) Pathway in Relation to Mammographic Breast Density and IGF Levels
Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 880 - 888.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S. Pechlivanis, B. Pardini, J. L. Bermejo, K. Wagner, A. Naccarati, L. Vodickova, J. Novotny, K. Hemminki, P. Vodicka, and A. Forsti
Insulin pathway related genes and risk of colorectal cancer: INSR promoter polymorphism shows a protective effect
Endocr. Relat. Cancer, September 1, 2007; 14(3): 733 - 740.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
K. Wagner, K. Hemminki, E. Grzybowska, R. Klaes, B. Burwinkel, P. Bugert, R. K. Schmutzler, B. Wappenschmidt, D. Butkiewicz, J. Pamula, et al.
Polymorphisms in genes involved in GH1 release and their association with breast cancer risk
Carcinogenesis, September 1, 2006; 27(9): 1867 - 1875.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
K Wagner, K Hemminki, E Israelsson, E Grzybowska, R Klaes, B Chen, D Butkiewicz, J Pamula, W Pekala, and A Forsti
Association of polymorphisms and haplotypes in the human growth hormone 1 (GH1) gene with breast cancer
Endocr. Relat. Cancer, December 1, 2005; 12(4): 917 - 928.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. Sweeney, M. A. Murtaugh, K. B. Baumgartner, T. Byers, A. R. Giuliano, J. S. Herrick, R. Wolff, B. J. Caan, and M. L. Slattery
Insulin-Like Growth Factor Pathway Polymorphisms Associated with Body Size in Hispanic and Non-Hispanic White Women
Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1802 - 1809.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.